Key issues that need to be considered while revising the current annex of the European Council Recommendation (2003) on cancer screening.
European Council
European Union
cancer screening
Journal
International journal of cancer
ISSN: 1097-0215
Titre abrégé: Int J Cancer
Pays: United States
ID NLM: 0042124
Informations de publication
Date de publication:
01 07 2020
01 07 2020
Historique:
received:
03
10
2019
revised:
26
11
2019
accepted:
09
01
2020
pubmed:
24
1
2020
medline:
18
3
2021
entrez:
24
1
2020
Statut:
ppublish
Résumé
The 2003 European Council recommendation urging the Member States to introduce or scale up breast, cervical and colorectal cancer screening through an organized population-based approach has had a remarkable impact. We argue that the recommendation needs to be updated for at least two sets of reasons. First, some of the current clinical guidelines include new tests or protocols that were not available at the time of the Council document. Some have already been adopted by organized screening programs, such as newly defined age ranges for mammography screening, Human Papillomavirus (HPV)-based cervical cancer screening, fecal immunochemical test (FIT) and sigmoidoscopy for colorectal cancer screening. Second, the outcomes of randomized trials evaluating screening for lung and prostate cancer have been published recently and the balance between harms and benefits needs to be pragmatically assessed. In the European Union, research collaboration and networking to exchange and develop best practices should be regularly supported by the European Commission. Integration between primary and secondary preventive strategies through comprehensive approaches is necessary not only to maximize the reduction in cancer burden but also to control the rising trend of other noncommunicable diseases sharing the same risk factors.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
9-13Informations de copyright
© 2020 International Agency for Research on Cancer (IARC/WHO); licensed by UICC.
Références
European Commission. Council recommendation of 2 December 2003 on cancer screening (2003/878/EC). Brussels: European Union, 2003. 5.
Basu P, Ponti A, Anttila A, et al. Status of implementation and organization of cancer screening in the European Union member states-summary results from the second European screening report. Int J Cancer 2018;142:44-56.
Andermann A, Blancquaert I, Beauchamp S, et al. Revisiting Wilson and Jungner in the genomic age: a review of screening criteria over the past 40 years. Bull World Health Organ 2008;86:317-9.
Dobrow MJ, Hagens V, Chafe R, et al. Consolidated principles for screening based on a systematic review and consensus process. CMAJ 2018;190:E422-9.
Dimitrova N, Saz Parkinson Z, Bramesfeld A, et al., eds. European guidelines for breast cancer screening and diagnosis-the European breast guidelines. Luxembourg: European Union, 2016. 32.
International Agency for Research on Cancer. IARC handbooks of cancer prevention volume 15. Breast cancer screening. Lyon: IARC, 2015. 481.
Anttila A, Arbyn A, de Vuyst H, et al. Eds. European guidelines for quality Assurance in Cervical Cancer Screening [Supplements], 2nd edn. Luxembourg: European Union, 2015. 194.
Ronco G, Dillner J, Elfström KM, et al. International HPV screening working group. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet 2014;383:524-32.
Segnan N, Patnick J, von Karsa L, eds. European guidelines for quality assurance in colorectal cancer screening and diagnosis. Luxembourg: European Union, 2010. 450.
Atkin W, Wooldrage K, Parkin DM, et al. Long term effects of once-only flexible sigmoidoscopy screening after 17 years of follow-up: the UKflexible sigmoidoscopy screening randomised controlled trial. Lancet 2017;389:1299-311.
Holme Ø, Schoen RE, Senore C, et al. Effectiveness of flexible sigmoidoscopy screening in men and women and different age groups: pooled analysis of randomised trials. BMJ 2017;356:i6673.
Aberle DR, Adams AM, Berg CD, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011;365:395-409.
Bach PB, Mirkin JN, Oliver TK, et al. Benefits and harms of CT screening for lung cancer: a systematic review. JAMA 2012;307:2418-29.
Robbins HA, Callister M, Sasieni P, et al. Benefits and harms in the National Lung Screening Trial: expected outcomes with a modern management protocol. Lancet Respir Med 2019;7:655-6.
Oudkerk M, Devaraj A, Vliegenthart R, et al. European position statement on lung cancer screening. Lancet Oncol 2017;18:e754-66.
De Koning H, Van Der Aalst C, Ten Haaf K, et al. Effects of volume CT lung cancer screening: mortality results of the NELSON randomised controlled population based trial: PL02.05. J Thorac Oncol 2018;13:S185.
Schröder FH, Hugosson J, Roobol MJ, et al. Screening and prostate cancer mortality: results of the European randomised study of screening for prostate cancer (ERSPC) at 13 years of follow-up. Lancet 2014;384:2027-35.
Ilic D, Djulbegovic M, Jung JH, et al. Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis. BMJ 2018;362:k3519.
Cuzick J, Thorat MA, Andriole G, et al. Prevention and early detection of prostate cancer. Lancet Oncol 2014;15:e484-92.
Lönnberg S, Šekerija M, Malila N, et al. Chapter 4. Cancer screening: policy recommendations on governance, organization and evaluation of cancer screening. In: Albreht T, Kiasuwa R, van den Bulcke M, eds European guide on quality improvement in comprehensive cancer control. Ljubljana/Brussels: National Institute of Public Health/Scientific Institute of Public Health, 2017. 39-75.
Elfström KM, Arnheim-Dahlström L, von Karsa L, et al. Cervical cancer screening in Europe: quality assurance and organisation of programmes. Eur J Cancer 2015;51:950-68.
Májek O, Anttila A, Arbyn M, et al. The legal framework for European cervical cancer screening programmes. Eur J Public Health 2019;29:345-50.
Anttila A, Lönnberg S, Ponti A, et al. Towards better implementation of cancer screening in Europe through improved monitoring and evaluation and greater engagement of cancer registries. Eur J Cancer 2015;51:241-51.
Deandrea S, Molina-Barceló A, Uluturk A, et al. Presence, characteristics and equity of access to breast cancer screening programmes in 27 European countries in 2010 and 2014. Results from an international survey. Prev Med 2016;91:250-63.
Armaroli P, Villain P, Suonio E, et al. European code against cancer, 4th edition: cancer screening. Cancer Epidemiol 2015;39:S139-52.
Albreht T, Kiasuwa R, van den Bulcke M, eds. European guide on quality improvement in comprehensive cancer control. Ljubljana/Brussels: National Institute of Public Health/Scientific Institute of Public Health, 2017. 188.